Dexamethasone Ophthalmic
Drugone drop daily in each eye with retinopathy of prematurity of a predefined stage.
Other names: dexafree
NCT Number: NCT05387941
Background and study aims
When an infant is born premature, the blood vessels in the eyes have not developed fully on the retina, and can start to grow incorrectly and result in blindness. To prevent this from happening, premature infants are often screened, and treated with laser or injections into the eye to prevent retinal detachment. A new treatment strategy with steroid eye drops have been found to prevent serious blood vessel growth. The treatment is commonly used in older children and adults to treat different inflammatory conditions, but how the drop is absorbed in premature infants and if there is any risk of side-effects is poorly investigated. The aim of this study is to document how the steroid drop is absorbed and excreted in premature infants and to study if there is a risk of any side effects.
Who can participate?
Premature infants born before gestational age week 30, that undergo eye-screening at Sahlgrenska University Hospital in Gothenburg and Skånes University Hospital in Malmö and Lund or at Helsingborg Hospital, in the need for steroid eye-drop treatment against pathological vessels. It is not possible to participate if the infant has received systemic steroid treatment 2 weeks prior to the eye-drop treatment, or has an ongoing ocular infection.
What does the study involve?
The study involves blood and saliva samples according to a specific protocol designed to be able to learn about the uptake and breakdown of the steroid in premature infants. Measurements of blood pressure, growth and a few urine samples will also be collected during the treatment period usually lasting for some weeks.
At 2.5 and 5 years of age, visual acuity, refractive errors and retinal thickness measurements will be noted.
What are the possible benefits and risks of participating?
The infant will receive steroid eye-drops that have been noted to heavily reduce the number of infants that develop retinal changes that require injections or laser treatment.
The blood samples have been reduced to an absolute minimum in volume and numbers, but will entail some extra samplings from the infant.
The infant will be rigorously checked with regard to any possible side effects from the steroid treatment. Possible but unlikely side effects from the low dose in eye drops are; elevated blood pressure, retarded growth, lowered endogenous steroid production during the eye-drop treatment, increase in blood glucose, and an increase in intra-ocular pressure.
Looking for future studies?
Notify MeUp to 30 week
All sexes
Interventional
Phase 1
Skåne University Hospital, Lund, Skåne County, Sweden
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
one drop daily in each eye with retinopathy of prematurity of a predefined stage.
Other names: dexafree
Time frame: up to 14 weeks
Half-life of dexamethasone- t½, hours
Time frame: up to 14 weeks
Maximum plasma concentration- Cmax, nmol/L
Time frame: up to 14 weeks
Half-life of dexamethasone- t½, hours
Time frame: up to 14 weeks
Maximum saliva concentration- Cmax, nmol/L
Time frame: up to 14 weeks
tmax, hours
Time frame: up to 14 weeks
tmax, hours
Time frame: up to 14 weeks
AUC0-t, nmol.h/L
Time frame: up to 14 weeks
AUC0-t, nmol.h/L
Time frame: up to 14 weeks
AUC0-∞, nmol.h/L
Time frame: up to 14 weeks
AUC0-∞, nmol.h/L
Time frame: up to 14 weeks
CL/F, L/h
Time frame: up to 14 weeks
Vz/F, L
Time frame: up to 14 weeks
Endogenous levels of corticosteroids, nmol/L
Time frame: up to 14 weeks
Endogenous levels of corticosteroids, nmol/L
Time frame: Up to 14 weeks
Time from detection of type 2 ROP to type 1 ROP, days
Time frame: Up to 14 weeks
recurrences after laser/anti-VEGF treatment, percentage
Time frame: after 2.5 years
Retinal thickness, micrometers
Time frame: after 5 years
Retinal thickness, micrometers
Time frame: after 2.5 years
Visual acuity according to Snellen, fraction
Time frame: after 2.5 years
Refractive power, diopters
Time frame: after 5 years
Visual acuity according to Snellen, fraction
Time frame: after 5 years
refractive power, diopters
Region Skane
Other
Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants With Retinopathy of Prematurity- a Feasibility Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02820662
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Dijon, France
View Trial DetailsNCT06517836
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Portland, Oregon, United States
View Trial DetailsNCT05133999
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Paris, France
View Trial DetailsNCT05304949
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases
Daegu, Dalseo gu, South Korea
View Trial Details